DESIGN, SYNTHESIS AND IN VITRO EVALUATION OF ANTIBACTERIAL AND ANTIADHESIVE POTENTIALS OF SOME SUBSTITUTED IMIDAZOLONES DERIVATIVES OF CINNAMALDEHYDE

BY
Abdelsattar M. Omar,* a,b and Mahmoud A. Elfakyc

FROM
a Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Al-Sulaymanyah, Jeddah 21589, Saudi Arabia.
b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
c Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Al-Sulaymanyah, Jeddah 21589, Saudi Arabia.

ABSTRACT
The cells of microorganisms often stick together and adhere to biotic and inert surfaces to form coats (biofilms) that are impenetrable and often highly resistant to antibiotics, as well as being adaptive to immune responses of the host. The aim of this study is to develop drugs that are able to prevent cell adhesion and/or penetrate biofilm layer and reach the bacteria to render them harmless. trans-Cinnamaldehyde, found in oils and cinnamon barks, and curcumin found in turmeric have been found to hold such pharmacologic properties. The newly developed product hybrids were evaluated for their ability to exert in vitro antibacterial activity as well as their potential as bacterial anti-adhesive agents on several different bacteria. In summary, we have developed several novel compounds that show both antibacterial and anti-adhesive properties. Although the compounds are not as potent as the positive controls, they serve as lead for further structural modification to develop more potent derivatives.

Key words: Synthesis, Antibacterial, Bacterial Anti-adhesive, biofilm, Imidazolone, Cinnamaldehyde

Introduction
Almost all microorganisms exert survival mechanism through the formation of biofilms, which is an association of the microbial cells to one another on inert or biological surfaces within a self-produced matrix of extracellular polymeric substance (Sekhar et al., 2009). Biofilms protect its inhabitants from predators, biocides, dehydration and other extreme environmental conditions (Dunne, 2002). Adhesion of the bacteria is the primary step taken by the bacteria that leads to pathogenic infections, and that involves resulting in nosocomial and community infections and posing as a significant threat to public health because of their impenetrable and resistance to most antibiotics (Costerton et al., 1999) (Khan et al., 2014). Several intrinsic mechanisms have been postulated to explain the high resistance nature of biofilms (Nickel and Costerton, 1993). These include limited diffusion, enzymes that cause neutralization, slow growth rate, biofilm phenotype as adaptive mechanisms and heterogeneous functions (Anderl et al., 2000), (Lewis, 2001), (Stewart and Franklin, 2008), (Estela and Alejandro, 2012). Examples of biofilm-implicated infections are those by E. coli, H.
influenza, S. aureus, S. epidermidis, P. aeruginosa, causing many diseases with deadly
effects if kept untreated (Sekhar et al., 2009), (Larson et al., 2003, Jensen et al., 2007),
(Novick and Geisinger, 2008, Lyczak et al., 2002), (Otto et al., 1998, Vadyvaloo and
Otto, 2005). (Naves et al., 2010). The extracellular matrix of certain pathogens, e.g. S.
aureus biofilms is formed by recycled cytoplasmic proteins, which allows the bacteria to
adapt to its environment and also promote production of mixed-species (Foulston et al.,
2014).

There is an increasing focus to develop antibiotics that can penetrate the biofilm
layer or even eradicate the biofilms enclosing the bacteria to make the antibiotics reach
their target (Liu et al., 2004, Kim et al., 2012). Curcumin (Fig. 1) an active ingredient of
turmeric has been shown to be effective in inhibiting the formation of biofilms; making
this compound a potential treatment for pathogens (Karaman et al., 2013). trans-
Cinnamaldehyde a constituent of cinnamon bark or found in cinnamon oil has also been
shown to significantly decrease the production of two virulence factors, A and α-toxin
in S aureus (Smith-Palmer et al., 2004). Low levels of trans-cinnamaldehyde have also
been noted to inhibit the cell-density dependent on the regulation of gene expression in
E. coli and biofilm synthesis in Vibrio spp. (Brackman et al., 2008). Additionally, trans-
cinnamaldehyde has been shown to reduce the expression of several virulence genes
essential for Uropathogenic Escherichia coli (UPEC) motility, host cell attachment and
invasion. trans-Cinnamaldehyde has been recognized by the FDA as a safe molecule for
use in food, and sub-chronic and chronic studies show this compound to have no
adverse effects (Adams et al., 2004). These findings suggest that both trans-
cinnamaldehyde and curcumin are potential candidates for the inhibition of biofilm
production, as well as anti-adhesive agents (Amalaradjou et al., 2011).

Curcumin and trans-Cinnamaldehyde (Fig. 1) contain a common core structural
moiety, phenyl-alkyl-one; which we propose is important and/or essential for their
observed antibiotic pharmacologic activities. We decided to take advantage of this core
feature to produce novel agents by hybridizing the phenyl-alkyl-one with substituted
imidazolone (Fig. 1). The 3-alkylidene-4-imidazolone skeleton was selected as it
possesses a greater size and more importantly contains an already preserved electron-
withdrawing substructure. The electron-withdrawing groups in the compounds are
expected to improve their metabolic stability, as well as control the electrophilic
reactivity of the nucleus molecule while maintaining a “drug-like electrophile” core.
The newly developed natural product hybrids were evaluated for their ability to exert in
vitro antibacterial activity as well as their potential as bacterial anti-adhesive agents.

![Figure 1. Design of Curcumin and tCA hybrids.](image-url)
Chemistry

The syntheses of the intermediate and the target compounds are illustrated in scheme 1. The starting compound 4-fluorobenzoylglycine 1 was prepared according to a reported method (El-Araby et al., 2012). Using standard Erlenmeyer methodology (El-Araby et al., 2012, Dakin, 1929), the 4-fluorobenzoylglycine 1 was condensed with cinnamaldehyde 2 to produce the corresponding 2-(4-fluorophenyl)-4-((E)-3-phenylallylidene)oxazol-5(4H)-one 3. This oxazolone key intermediate 3 was subsequently reacted with a variety of aliphatic, aromatic and heterocyclic amines in the presence of dry pyridine to afford the targeted 3-substituted-2-(4-fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-ones 4 (Lokhandwala and Rai).

![Scheme 1](image)

Scheme 1. Synthesis of Imidazolone Derivatives

In vitro Antibacterial Evaluation

All newly synthesized target compounds 4a-o were tested for their in vitro antibacterial activity against the Gram positive bacteria, *Staphylococcus aureus* (ATCC 29213), *Staphylococcus epidermidis* (ATCC 12228) and *Bacillus subtilis* (ATCC 12228), and the Gram negative bacteria, *Escherichia coli* (ATCC 35218), *Pseudomonas aeruginosa* (ATCC 27853), *Proteus mirabilis* (ATCC 14153) and *Klebsiella pneumonia* (ATCC 700603).

As shown in Table 1, the majority of the tested compounds showed antibacterial activity towards most of the microorganisms. Compound 4d showed the broadest spectrum of activity against several bacteria with MIC values (62.5 µg/mL against *S. aureus*, *S. epidermidis*, *B. subtilis*, *P. aeruginosa* and *P. mirabilis*), followed closely by 4a (62.5 µg/mL against *S. aureus* and against *E. coli* and 125 µg/mL against *P. mirabilis*). Other compounds e.g. 4f (62.5 µg/mL against *S. aureus* and 125 µg/mL against *P. mirabilis* and *E. coli*), 4j (62.5 µg/mL against *S. aureus* and 125 µg/mL against *P. mirabilis* and *E. coli*) and 4n (62.5 µg/mL against *S. aureus*), then 4i (125
µg/mL against *P. mirabilis*, 4l (62.5 µg/mL against *S. aureus*) and 4m (125 µg/mL against *P. mirabilis*) also showed significant antibacterial activities, but only against a limited number of the bacteria. Compounds 4g (125 µg/mL against *S. aureus*), 4h (62.5 µg/mL against *S. aureus*), 4n (62.5 µg/mL against *S. aureus*) and 3 (125 µg/mL against *P. mirabilis*) showed the least antibacterial activity for the selected concentration range. These observed MIC results (62.5 or 125 µg/mL) compare with the MIC values of 0.1 - 18 µg/mL observed with ceftriaxone against all the bacteria, and 1.5 - 12.5 µg/mL with amoxicillin against selected bacteria.

Adherence assay of *S. aureus* ATCC 29213 to HCT 116 cells

The assay was carried out as described by Plotkowski *et al.* (1994) (*Plotkowski et al.*, 1994). Inhibition of adherence of *S. aureus* ATCC 29213 to HCT 116 ATCC ® CCL-247™ human colorectal carcinoma cells was established by incubating constant numbers of HCT 116 cells and bacteria for 2 hours, followed by addition of compounds at concentrations (6.25, 12.5, 25 and 50 μM) that are harmless to pro- and eukaryotic cells (Table 2). The results showed statistically-significant (*p* < 0.05) inhibition of adherence of *S. aureus* by compounds 4a (59.12% at 25 μM), 4b (69.57% at 6.25 μM), 4d (51.40% and 64.41% at 12.5 μM and 50 μM, respectively), 4e (68.22% at 12.5 μM), 4g (58.88% and 55.93% at 12.5 μM and 50 μM, respectively), 4j (51.40% at 12.5 μM), 4m (55.14% at 12.5 μM) and 4n (66.36% and 54.74% at 12.5 μM and 25 μM, respectively). The results also showed highly statistically-significant (*p* < 0.01) inhibition of the adherence of *S. aureus* ATCC 29213 to the same human colorectal carcinoma cells by compounds 4a (77.57% and 88.14% at 12.5 μM and 50 μM, respectively), 4b (86.92%, 95.62% and 100.00% at 12.5 μM, 25 μM and 50 μM, respectively), 4c (91.30%, 98.13%, 98.54% and 99.15% at the four concentrations tested), 4d (82.48% at 25 μM), 4e (88.13% at 25 μM), 4g (76.64% at 25 μM), 4h (88.32% at 25 μM), 4i (64.49% and 83.94% at 12.5 μM and 25 μM, respectively), 4k (76.64% at 25 μM) and 4n (80.43% at 6.25 μM). However, no inhibitory effect was observed for compounds 4f, 4l, 4o and 3 at any of the concentrations tested (Table 2).

### Statistical Analysis

A one-sample *t*-test was used to evaluate whether the inhibition of adherence of *S. aureus* ATCC 29213 to HCT 116 ATCC ® CCL-247™ human colorectal carcinoma cells was different from 0%. The GraphPad Prism program for Windows, Version 6, was used for data processing.

### Discussion

Biofilm formation is used by bacterial and other microbes as a survival mechanism by becoming impenetrable and resistant to antibiotics. Biofilms are also involved in a wide variety of microbial infections. Over the past several years, compounds derived from plants have been shown not only to have antibacterial properties but the ability to inhibit bacterial adhesion and biofilm formation (Palaska *et al.*, 2013). These properties make these compounds display some strong advantages over the use of antibiotics, since, as the adhesion would be prevented, the drug would perform more efficiently at an earlier stage of the disease, and it would not depend on the bacterial multiplication rates and most importantly, would not foster antibiotic resistance development. Therefore, the development of antiadhesives and antibacterial agents would serve as promising solutions for the resistance displayed by the bacteria because of their biofilms.
In our current study, we have synthesized 3-substituted-2-(4-fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-ones derivatives, by hybridizing the cinnamaldehyde/curcumin core structural moiety, phenyl-alkyl-one with substituted imidazolone. We expect these compounds to exhibit antibacterial effect by inhibiting bacterial adhesion and biofilm formation and killing them. When tested against the bacteria, S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, P. mirabilis and K. pneumonia, most of the compounds showed antibacterial activity with compound 4d showing the broadest spectrum of activity against five of the seven tested bacterial, all with MIC value of 62.5 µg/mL but significantly lower than the observed for ceftriaxone (CTX) and amoxicillin (AMX) (0.14-18) for the same bacteria. Worth mentioning is that 4a showed the highest activity among all the tested compounds against E. coli with MIC of 15.56 µg/mL. In addition it inhibited two other bacteria with MIC values of 62.5 and 125.

It appears that the alkyl or aryl substitution at position 3 of the imidazolone are detrimental for the antibacterial activity while the non-substituted possessed significant antibacterial activity toward the majority of the microorganisms.

Pathogenesis of S. aureus and for that matter, all antibacterial are associated with their adhesive mechanisms and biofilm formation; therefore, the inhibition of the microbes adherence would be a most promising measure of attenuating disease progressions. We measured the average inhibition of adherence of S. aureus. The results showed that most of the compounds presented significant inhibition of adherence, either substituted or non-substituted at position 3 of the imidazolone.

In summary, we have developed several novel compounds that show both antibacterial and anti-adhesive properties. Although the compounds are not as potent as the positive controls, CTX and AMX, they serve as lead for further structural modification to develop more potent derivatives.
Table 1. Antibacterial activities of the compounds studied

<table>
<thead>
<tr>
<th>No.</th>
<th>Code</th>
<th>MICs (µg/mL) values</th>
<th>Gram-positive bacteria</th>
<th>Gram-negative bacteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>S. aureus</td>
<td>S. epidermidis</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>2</td>
<td>4a</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>3</td>
<td>4b</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>4</td>
<td>4c</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>5</td>
<td>4d</td>
<td>62.5</td>
<td>62.5</td>
<td>62.5</td>
</tr>
<tr>
<td>6</td>
<td>4e</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>7</td>
<td>4f</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>8</td>
<td>4g</td>
<td>125</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>9</td>
<td>4h</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>10</td>
<td>4i</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>11</td>
<td>4j</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>12</td>
<td>4k</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>13</td>
<td>4l</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>14</td>
<td>4m</td>
<td>&gt;500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>15</td>
<td>4n</td>
<td>62.5</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>16</td>
<td>4o</td>
<td>500</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
<tr>
<td></td>
<td>Ceftriaxone</td>
<td>CTX</td>
<td>0.14</td>
<td>2.3</td>
</tr>
<tr>
<td></td>
<td>Amoxcillin</td>
<td>AMX</td>
<td>1.56</td>
<td>12.5</td>
</tr>
<tr>
<td></td>
<td>Dimethyl sulfoxide</td>
<td>DMSO</td>
<td>&gt;500</td>
<td>&gt;500</td>
</tr>
</tbody>
</table>
Table 2. Average Inhibition of the adherence (%) of *S. aureus* ATCC 29213 to HCT 116 ATCC ® CCL-247™ human colorectal carcinoma cells

<table>
<thead>
<tr>
<th>No.</th>
<th>Code</th>
<th>Concentration (µM)</th>
<th>6.25</th>
<th>12.5</th>
<th>25</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td></td>
<td>-117.39</td>
<td>-30.84</td>
<td>12.41</td>
<td>-66.10</td>
</tr>
<tr>
<td>2</td>
<td>4a</td>
<td></td>
<td>-30.43</td>
<td>77.57**</td>
<td>59.12*</td>
<td>88.14**</td>
</tr>
<tr>
<td>3</td>
<td>4b</td>
<td></td>
<td>69.57*</td>
<td>86.92**</td>
<td>95.62**</td>
<td>100.00**</td>
</tr>
<tr>
<td>4</td>
<td>4c</td>
<td></td>
<td>91.30**</td>
<td>98.13**</td>
<td>98.54**</td>
<td>99.15**</td>
</tr>
<tr>
<td>5</td>
<td>4d</td>
<td></td>
<td>-52.17</td>
<td>51.40*</td>
<td>82.48**</td>
<td>64.41*</td>
</tr>
<tr>
<td>6</td>
<td>4e</td>
<td></td>
<td>0.00</td>
<td>68.22*</td>
<td>86.13**</td>
<td>40.68</td>
</tr>
<tr>
<td>7</td>
<td>4f</td>
<td></td>
<td>13.04</td>
<td>42.06</td>
<td>8.03</td>
<td>32.20</td>
</tr>
<tr>
<td>8</td>
<td>4g</td>
<td></td>
<td>-34.78</td>
<td>58.88*</td>
<td>76.64**</td>
<td>55.93*</td>
</tr>
<tr>
<td>9</td>
<td>4h</td>
<td></td>
<td>-134.78</td>
<td>-15.89</td>
<td>88.32**</td>
<td>10.17</td>
</tr>
<tr>
<td>10</td>
<td>4i</td>
<td></td>
<td>-52.17</td>
<td>64.49**</td>
<td>83.94**</td>
<td>47.46</td>
</tr>
<tr>
<td>11</td>
<td>4j</td>
<td></td>
<td>-213.04</td>
<td>51.40*</td>
<td>27.01</td>
<td>5.08</td>
</tr>
<tr>
<td>12</td>
<td>4k</td>
<td></td>
<td>26.09</td>
<td>49.53</td>
<td>76.64**</td>
<td>44.07</td>
</tr>
<tr>
<td>13</td>
<td>4l</td>
<td></td>
<td>-121.74</td>
<td>-49.53</td>
<td>0.73</td>
<td>-54.24</td>
</tr>
<tr>
<td>14</td>
<td>4m</td>
<td></td>
<td>39.13</td>
<td>55.14*</td>
<td>18.25</td>
<td>27.12</td>
</tr>
<tr>
<td>15</td>
<td>4n</td>
<td></td>
<td>80.43**</td>
<td>66.36*</td>
<td>54.74*</td>
<td>37.29</td>
</tr>
<tr>
<td>16</td>
<td>4o</td>
<td></td>
<td>-78.26</td>
<td>4.67</td>
<td>19.71</td>
<td>-22.03</td>
</tr>
</tbody>
</table>

* Significantly different from zero (*p* < 0.05) using one-sample *t*-test; ** highly significantly different from zero (*p* < 0.01) using one-sample *t*-test.

**Experimental General**

Melting points were determined in open capillary tubes using Electrothermal apparatus (Stuart, UK) and are uncorrected IR spectra were recorded using the potassium bromide method on Perkin-Elmer 1650 spectrophotometer and expressed in wave number (υmax) cm⁻¹.¹H-NMR and ¹³C-NMR spectra were measured in deuterated chloroform (CDCl₃) or deuterated dimethyl sulphoxide (DMSO-d₆) on Avance III 600 MHz spectrometer (Bruker, Germany) and chemical shifts were ex-pressed as ppm...
against TMS as internal reference (King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia). LCMS were run on Agilent 6130 Series, single quad. HPLC separation was run on 1200 SERIES HPLC using Chemstation Software. Purities were assessed by HPLC and were confirmed to be >95% for all final compounds. Reaction progress and compound purity were monitored by Thin Layer Chromatography (TLC) using silica gel matrix, L × W 5 cm × 20 cm, fluorescent indicator (Sigma-Aldrich® TLC Plates, USA) and dichloromethane: petroleum ether (4:1) or dichloromethane as eluent systems. The spots were visualized using an ultraviolet lamp (Vilber Lourmet, Marine La Vallee, France) at λ = 254 and 266 nm. Column chromatography was performed on silica gel 60 (particle size 0.06 mm - 0.20 mm).

The antibacterial activity of the synthesized compounds was tested against standard strains of seven bacteria. They were obtained from the microbiology laboratory, King Abdulaziz University Hospital, Jeddah, KSA. These strains included Gram-negative bacteria: Escherichia coli ATCC 35218 Bacillus subtilis ATCC 6633, Klebsiella pneumonia ATCC 700603, Pseudomonas aeruginosa ATCC 27853 Staphylococcus epidermidis ATCC 12228 and Gram-positive bacteria: Staphylococcus Aureus ATCC 29213 and P. mirabilis ATCC 14153.

Chemical Synthesis

Preparation of (Z)-2-(4-fluorophenyl)-4-((E)-3-phenylallylidene)oxazol-5(4H)-one (3):

A mixture of 4-flourobenzoylglycine (1) (1.97 g, 0.01 mol), cinnamaldehyde (2) (1.98 g, 1.88 ml, 0.015 mol), anhydrous sodium acetate (0.6 g, 0.07 mol) and acetic anhydride (5ml) was warmed on a boiling water bath with occasional stirring for 20 minutes. The resulting solution was refluxed for 1 hour, cooled and left in a refrigerator for an overnight. The produced yellow solid mass was filtered, washed with cold water then washed with petroleum ether, dried and crystalized from ethanol. Yield 2.5 g (85%). M.p. 151-153 °C.

General Procedure for the Preparation of (Z)-3-substituted-2-(4-fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4):

A mixture of (Z)-2-(4-fluorophenyl)-4-((E)-3-phenylallylidene)oxazol-5(4H)-one (3) (2.93 g, 0.01 mol), the appropriate amine (0.01 mol) and pyridine (10 ml) was taken in a 25 ml-tube of Thermal Integrity Reaction Station and the temperature was kept at 100 °C for 18 hours. The reaction mixture was poured onto crushed ice and neutralized with drops of conc. HCl. The solid separated out was filtered, washed with water, left to air-dry, then purified by flash column chromatography (silica gel, mixtures of petroleum ether/dichloromethane, 1:4, v/v) to afford the desired pure compounds (4a-4o).

(Z)-2-(4-Fluorophenyl)-3-phenyl-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4a):

The yellow solid crystals were obtained in 68% yield; m.p. 168 °C. 1H NMR (600 MHz, CDCl3) □ □ 7.85 (dd, J = 11.86, 15.62 Hz, 1H), 7.65 (d, J = 7.53 Hz, 2H), 7.57 (dd, J = 5.27, 8.66 Hz, 2H), 7.44 - 7.50 (m, 2H), 7.40 - 7.44 (m, 3H), 7.38 (d, J = 7.15 Hz, 1H), 7.27 (d, J = 11.67 Hz, 1H), 7.14 - 7.21 (m, 3H), 7.04 (t, J = 8.66 Hz, 2H); 13C NMR (151 MHz, CDCl3) □ □ 131.7, 131.6, 129.8, 129.8, 129.1, 128.7, 128.1, 127.6,
127.5, 123.9, 116.0, 115.9, 77.5, 77.2, 77.0; IR (FT-IR, cm⁻¹): 3052.9, 1736.9, 1710.5, 1602.4, 1489.0, 1365.0, 1296.5; LC-MS (ESI), RT = 7.5 min, m/z 369.0 [M + H]+

(Z)-3-Benzyl-2-(4-fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4b):

The yellowish solid crystals were obtained in 73% yield; m.p. 155 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (dd, J = 11.80 Hz, 1H), 7.60 - 7.69 (m, 4H), 7.31 - 7.46 (m, 6H), 7.26 (d, J = 11.80 Hz, 1H), 7.11 - 7.20 (m, 5H), 4.95 (s, 2H); ¹³C NMR (151 MHz, CDCl₃) δ 136.5, 131.1, 129.9, 129.3, 129.2, 129.1, 128.3, 128.1, 128.0, 126.9, 126.8, 123.8, 116.4, 116.3, 77.5, 77.2, 77.0, 45.5, 29.9; IR (FT-IR, cm⁻¹): 3043.3, 1709.8, 1630.4, 1598.0, 1495.0, 1362.5, 1238.9; LC-MS (ESI), RT = 11.0 min, m/z 383 [M + H]+

(Z)-2-(4-Fluorophenyl)-5-((E)-3-phenylallylidene)-3-(pyridin-3-yl)-3,5-dihydro-4H-imidazol-4-one (4c):

The yellow solid crystals were obtained in 51% yield; m.p. 175 °C. ¹H NMR (600 MHz, CDCl₃) δ 8.66 (d, J = 4.14 Hz, 1H), 8.43 (s, 1H), 7.84 (dd, J = 11.67, 15.43 Hz, 1H), 7.66 (d, J = 7.53 Hz, 2H), 7.58 - 7.63 (m, 1H), 7.55 (dd, J = 5.27, 8.28 Hz, 2H), 7.35 - 7.48 (m, 5H), 7.20 (d, J = 15.43 Hz, 1H), 7.08 (t, J = 8.47 Hz, 2H); ¹³C NMR (151 MHz, CDCl₃) δ 137.8, 134.3, 131.9, 131.3, 131.3, 131.1, 129.9, 128.9, 128.0, 123.4, 116.2, 116.0, 77.2, 77.0, 76.8; IR (FT-IR, cm⁻¹): 3071.4, 1279.6, 1716.9, 1600.4, 1494.1, 1433.3, 1365.0, 1296.6; LC-MS (ESI), RT = 5.1 min, m/z 370 [M + H]+

(Z)-2-(4-Fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4d):

The yellowish solid crystals were obtained in 48% yield; m.p. 292- 93 °C.; ¹H NMR (850 MHz, DMSO-d₆) δ 12.05 (s, 1 H), 8.17 - 8.22 (m, 2 H), 8.08 - 8.14 (m, 1 H), 7.62 - 7.70 (m, 2 H), 7.58 (d, J=7.79 Hz, 1 H), 7.42 - 7.48 (m, 4 H), 7.35-7.41 (m, 1 H), 7.30 (d, J=15.57 Hz, 1 H), 6.96 (dd, J=11.42, 1.04 Hz, 1 H); ¹³C NMR (214 MHz, DMSO-d₆) δ 171.4, 158.4, 141.9, 141.7, 130.3, 130.3, 130.0, 129.9, 129.8, 129.6, 129.5, 127.9, 127.7, 127.3, 125.2, 124.0, 116.7, 116.6; IR (FT-IR, cm⁻¹): 3132.2, 3063.8, 1691.6, 1630.8, 1504.2, 1438.4, 1320.8, 1159.94; LC-MS (ESI), RT = 4.6 min, m/z 293 [M + H]+

(Z)-2-(4-Fluorophenyl)-3-methyl-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4e):

The yellowish solid crystals were obtained in 66% yield; m.p. 128 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.69 - 7.91 (m, 2H), 7.55 - 7.69 (m, 1H), 7.33 - 7.44 (m, 2H), 7.14 - 7.32 (m, 4H), 3.31 - 3.42 (m, 2H), 1.61 (s, 3H); ¹³C NMR (214 MHz, DMSO-d₆) δ 165.62, 164.36, 160.40, 160.3, 159.21, 159.13, 155.12, 154.44, 139.09, 138.14, 134.68, 131.55, 126.07, 120.75, 118.80, 24.37; IR (FT-IR, cm⁻¹): 3038.56, 1709.3, 1628.3, 1597.9, 1504.2, 1362.4, 1230.8; LC-MS (ESI), RT = 5.4 min, m/z 306.9 [M + H]+

(Z)-2-(4-Fluorophenyl)-3-(4-methylpiperazin-1-yl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4f):
The yellowish solid crystals were obtained in 57% yield; m.p. 231-33 °C. \(^1\)H NMR (600 MHz, CDCl\(_3\)) 8 8.30 (dd, J = 5.65, 9.03 Hz, 2H), 7.76 (dd, J = 11.67, 15.43 Hz, 1H), 7.61 - 7.65 (m, 2H), 7.34 - 7.45 (m, 2H), 7.29 (s, 3H), 7.18 - 7.23 (m, 2H), 7.08 - 7.13 (m, 2H), 4.14 (br. s., 2H), 2.39 (br. s., 4H), 1.65 (br. s., 3H); IR (FT-IR, cm\(^{-1}\))): 2928.5, 2866.7, 2787.2, 1704.0, 1624.5, 1603.9, 1549.0, 1453.8, 1283.0, 1230.0; LC-MS (ESI), RT = 4.9 min, m/z 391.0 [M + H]\(^+\)

(Z)-2-(4-Fluorophenyl)-5-((E)-3-phenylallylidene)-3-propyl-3,5-dihydro-4H-imidazol-4-one (4g):

The yellowish solid crystals were obtained in 65% yield; m.p. 119 °C. \(^1\)H NMR (400 MHz, CDCl\(_3\)) 8 7.67 - 7.86 (m, 3H), 7.62 (d, J = 7.28 Hz, 2H), 7.33 - 7.43 (m, 3H), 7.09 - 7.31 (m, 4H), 3.66 - 3.81 (m, 2H), 1.52 - 1.78 (m, 3H), 0.88 (t, J = 7.40 Hz, 3H); \(^1\)^C NMR (214 MHz, CDCl\(_3\)) 8 163.9, 160.1, 136.3, 130.6, 129.6, 128.9, 128.7, 128.4, 127.9, 124.2, 124.1, 123.6, 116.4, 116.3, 116.0, 43.4, 43.3, 22.4, 22.0, 11.2, 11.1; IR (FT-IR, cm\(^{-1}\)): 2971.5, 2932.0, 2869.0, 1701.7, 1628.1, 1628.1, 1599.2, 1499.3, 1281.1, 1228.5; LC-MS (ESI), RT = 8.1 min, m/z 335.0 [M + H]\(^+\)

3-((Z)-2-(4-Fluorophenyl)-5-oxo-4-((E)-3-phenylallylidene)-4,5-dihydro-1H-imidazol-1-yl)benzonitrile (4h):

The yellowish solid crystals were obtained in 72% yield; m.p. 203-05 °C. \(^1\)H NMR (600 MHz, CDCl\(_3\)) 8 7.84 (dd, J = 11.67, 15.81 Hz, 1H), 7.61 - 7.73 (m, 3H), 7.51 - 7.60 (m, 3H), 7.36 - 7.50 (m, 4H), 7.27 - 7.32 (m, 2H), 7.13 - 7.25 (m, 1H), 6.99 - 7.13 (m, 2H); \(^1\)^C NMR (151 MHz, CDCl\(_3\)) 8 136.3, 132.5, 131.7, 131.5, 131.5, 130.6, 130.1, 129.2, 128.3, 128.2, 123.6, 116.5, 116.3, 77.5, 77.2, 77.0; IR (FT-IR, cm\(^{-1}\)): 3066.1, 2235.3, 1707.9, 1631.4, 1496.9, 1481.1, 1370.3, 1238.4, 1151.4; LC-MS (ESI), RT = 7.1 min, m/z 394.0 [M + H]\(^+\)

(Z)-2-(4-Fluorophenyl)-3-(4-hydroxyphenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4i):

The yellowish solid crystals were obtained in 57% yield; m.p. 92-934 °C. \(^1\)H NMR (600 MHz, CDCl\(_3\)) 8 7.85 (dd, J = 11.67, 15.81 Hz, 1H), 7.62 - 7.66 (m, 1H), 7.58 - 7.62 (m, 1H), 7.37 - 7.44 (m, 3H), 7.26 - 7.30 (m, 2H), 7.16 - 7.21 (m, 1H), 6.96 - 7.04 (m, 4H), 6.77 - 6.83 (m, 2H); \(^1\)^C NMR (151 MHz, CDCl\(_3\)) 8 156.8, 136.4, 133.0, 131.9, 131.7, 130.1, 129.2, 129.1, 128.9, 128.9, 128.3, 128.2, 123.8, 117.0, 117.0, 116.1, 116.0, 115.9, 115.8, 77.5, 77.2, 77.0; IR (FT-IR, cm\(^{-1}\)): 3029.2, 1707.9, 1692.1, 1626.1, 1594.5, 1510.1, 1370.3, 1272.7, 1222.6, 1156.7; LC-MS (ESI), RT = 4.9 min, m/z 385.0 [M + H]\(^+\)

(Z)-2,3-bis(4-Fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4j):

The yellowish solid crystals were obtained in 57% yield; m.p. 135-37 °C. \(^1\)H NMR (850 MHz, DMSO-d\(_6\)) 8 7.71 - 7.75 (m, 1H), 7.69 (d, J = 7.27 Hz, 1H), 7.59 (d, J = 7.79 Hz, 1H), 7.54 - 7.57 (m, 1H), 7.47 - 7.50 (m, 1H), 7.45 (t, J = 7.53 Hz, 2H), 7.39 - 7.43 (m, 2H), 7.31 - 7.39 (m, 5H), 7.23 - 7.29 (m, 2H); IR (FT-IR, cm\(^{-1}\)): 3058.2, 1712.2, 1628.8, 1507.4, 1415.1, 1285.9, 1222.6, 1151.4; LC-MS (ESI), RT = 9.0 min, m/z 386.9 [M + H]\(^+\)
(Z)-2-(4-Fluorophenyl)-3-(furan-2-ylmethyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4k):

The yellowish solid crystals were obtained in 48% yield; m.p. 145 °C. 1H NMR (400 MHz, CDCl3) δ 7.62 - 7.76 (m, 2H), 7.48 - 7.55 (m, 1H), 7.05 - 7.32 (m, 7H), 6.12 - 6.26 (m, 1H), 4.80 (s, 1H), 1.51 (s, 4H); LC-MS (ESI), RT = 7.3 min, m/z 373.0 [M + H]⁺

(Z)-2-(4-Fluorophenyl)-3-(2-morpholinoethyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4l):

The yellowish solid crystals were obtained in 44% yield; m.p. 163 °C. 1H NMR (400 MHz, CDCl3) δ 7.82 - 7.89 (m, 2H), 7.62 (d, J = 7.28 Hz, 2H), 7.35 - 7.44 (m, 3H), 7.28 (br. s., 1H), 7.22 - 7.27 (m, 2H), 7.10 - 7.21 (m, 2H), 3.90 (t, J = 6.27 Hz, 2H), 3.54 - 3.61 (m, 4H), 2.50 (t, J = 6.27 Hz, 2H), 2.31 - 2.37 (m, 4H); IR (FT-IR, cm⁻¹): 3072.7, 2960.9, 2796.0, 1704.0, 1630.4, 1506.7, 1418.4, 1350.7, 1224.2, 1150.6; LC-MS (ESI), RT = 4.9 min, m/z 406.0 [M + H]⁺

(Z)-2-(4-Fluorophenyl)-3-(4-methoxyphenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4m):

The yellowish solid crystals were obtained in 48% yield; m.p. 198-200 °C. 1H NMR (600 MHz, CDCl3) δ 7.84 (dd, J = 11.67, 15.81 Hz, 1H), 7.65 (d, J = 7.15 Hz, 1H), 7.58 - 7.63 (m, 2H), 7.55 (dd, J = 5.27, 8.66 Hz, 1H), 7.40 - 7.45 (m, 1H), 7.34 - 7.40 (m, 1H), 7.27 - 7.28 (m, 1H), 7.08 - 7.17 (m, 3H), 7.01 - 7.07 (m, 2H), 6.95 - 7.00 (m, 2H), 3.85 (s, 3H); IR (FT-IR, cm⁻¹): 3010.4, 1709.5, 1638.6, 1547.5, 1441.2, 1415.9, 1357.9, 1215.9; LC-MS (ESI), RT = 9.9 min, m/z 399.0 [M + H]⁺

(Z)-3-(4-Chlorophenyl)-2-(4-fluorophenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4n):

The yellowish solid crystals were obtained in 65% yield; m.p. 198°C. 1H NMR (600 MHz, CDCl3) δ 7.84 (dd, J = 11.67, 15.81 Hz, 1H), 7.65 (d, J = 7.15 Hz, 2H), 7.57 (dd, J = 5.46, 8.85 Hz, 2H), 7.37 - 7.45 (m, 5H), 7.27 (d, J = 11.67 Hz, 1H), 7.18 (d, J = 15.81 Hz, 1H), 7.13 (d, J = 8.66 Hz, 2H), 7.08 (t, J = 8.66 Hz, 2H); 13C NMR (214 MHz, CDCl3) δ 168.8, 165.1, 163.9, 157.4, 143.7, 136.2, 134.3, 132.9, 131.5, 131.4, 131.3, 129.8, 128.9, 128.5, 128.4, 128.0, 127.9, 124.6, 124.0, 123.5, 116.0, 116.0, 115.9, 115.9; IR (FT-IR, cm⁻¹): 3063.6, 1729.6, 1719.4, 1636.8, 1595.4, 1494.1, 1413.1, 1365.0, 1238.4; LC-MS (ESI), RT = 11.8 min, m/z 403.0 [M + H]⁺

(Z)-2-(4-Fluorophenyl)-3-(3-methoxyphenyl)-5-((E)-3-phenylallylidene)-3,5-dihydro-4H-imidazol-4-one (4o):

The yellowish solid crystals were obtained in 42% yield; m.p. 119°C. 1H NMR (600 MHz, CDCl3) δ 7.84 (dd, J = 11.67, 15.81 Hz, 1H), 7.57 - 7.69 (m, 3H), 7.55 (dd, J = 5.27, 8.66 Hz, 1H), 7.32 - 7.46 (m, 4H), 7.26 (d, J = 11.29 Hz, 1H), 7.09 - 7.19 (m, 1H), 7.01 - 7.08 (m, 2H), 6.94 - 7.00 (m, 1H), 6.71 - 6.79 (m, 2H), 3.78 (s, 3H); IR (FT-IR, cm⁻¹): 2838.5, 1929.6, 1714.4, 1628.0, 1595.4, 1489.0, 1299.1, 1225.7, 1152.34; LC-MS (ESI), RT = 8.8 min, m/z 299 [M + H]⁺
Antibacterial Evaluation

The antibacterial activities were evaluated regarding the minimum inhibitory concentrations (MICs) by using microbroth dilution assays according to the CLSI guidelines (Wayne, 2006). Using DMSO to dissolve all of the tested compounds, it was also used as negative control with concentrations range from 0.12 to 500 µg/mL. Commercial antibiotics amoxicillin, ceftriaxone and nystatin were used as a positive control. The bacterial stock cultures were maintained on Muller-Hinton agar plates. A loopful of overnight bacterial cells from the agar plates was inoculated into 5 mL normal saline (85% NaCl) and turbidity was adjusted to 1-5 x 10⁶ CFU/ml. Ten µL of standardized bacterial culture was introduced into 96 wells tissue culture plates containing 100 µL Muller-Hinton broth/well with various concentrations of the compounds reviewed. The MIC was defined as the lowest possible concentration which could inhibit the growth of the bacterial strains. All of the analysis were performed in triplicate and MIC’s values are given in µg/mL.

Adherence assay of S. aureus ATCC 29213 to HCT 116 cells

One hundred microliters of the bacterial suspension (1-5 X 10⁸ CFU/ml) were added to HCT 116 ATCC ® CCL-247™ (Human colorectal carcinoma) (Supplied from King Fahd Research center, Jeddah, KSA) in tissue culture plate wells containing 100 µL antibiotic free RPMI 1640 media (Gibco, ThermoFisher Scientific, MA, USA). Then incubated for 2 hour, the monolayers with attached bacteria were washed three times with phosphate buffer saline (PBS) (Gibco, ThermoFisher Scientific, MA, USA). The total number of the cells (adherent to and uptaken by HCT 116 cells) and the number of the cells uptaken by the HCT 116 cells were determined. Then, by subtracting the number of bacterial cells uptaken by the HCT 116 cells from the total number of cells, the number of adherent cells can be determined. The total number of the cell was determined as follows; after addition of the bacterial suspension on HCT 116 and incubation for 2 hours, the monolayers with attached bacteria were washed three times with PBS. Then, lysis of the epithelial cell was carried out by treating with PBS containing 0.025 % trypsin (Sigma-Aldrich, Germany) and 1% tween 20 (Sigma-Aldrich, Germany) for 30 min at 37 °C. Aliquots of the cell lysates were diluted and placed on Trypticase Soy agar to quantify the number of viable cells. The number of uptaken cells was determined as follows; after incubation and washing 3 times with PBS, the monolayers with attached cell were rinsed with tissue culture medium (as described above) containing 300 µg/ml gentamicin for 1 hour to kill all the external bacterial cell. After removal of antibiotic containing medium, the HCT 116 cells were washed and treated with the lysis solution (as described above). Then, the number of cells uptaken can be determined by viable count technique. Assays were carried out in triplicate. The the number of adhered bacteria (CFU·mL⁻¹) relative to the total number of bacteria added initially × 100 was used to calculate the adherence percentage (%). The percentage of inhibition by compounds was calculated as [1 – (% Adherence sample/% Adherence control)] × 100.

REFERENCES


Lokhandwala, S. and Rai, S. 'Synthesis And In Vitro Microbial Evaluation Of Some Novel Imidazo-5-one Derivatives'.


تصميم وتشييد وتقسيم المضادات المحتملة للبكتيريا والإملاءات مختبرياً لبعض الإمدازولون المشتقات من السينمالدهيد

للسادة الدكاترة

عبد الستار منصور عبيد عمر۱ و محمد علي الخالق الفقي۲

۱ قسم الكيمياء الصيدلانية، كلية الصيدلة، جامعة الملك عبدالعزيز، السليمانية، جدة ۲۱۵۸۹، المملكة العربية السعودية.

۲ قسم الكيمياء الصيدلانية، كلية الصيدلة، جامعة الأزهر، القاهرة ۱۱۸۴، مصر.

خلايا المضادات الحيوية، كثيراً ما تتقصى بعضها البعض على المضادات الحيوية بالعملية التشكيلية (الاستجابات المتنوعة التي لا يمكن اختراقها أو غالباً تكون شديدة المقاومة للمضادات الحيوية)، وكذلك لديها قدرة على التركيز مع الاستجابات المستمرة للمضادات المضادة للبكتيريا، ولهذا من فوائد هذه الدراسة هو تطوير عقاقير قادرة على منع التخصص في الخلايا أو اختراق طبقة بروتين والوصول إلى البكتيريا لجعلها غير ضارة. وكما تم في السينمالدهيد، الموجود في الزيوت أو جزءات الفرقة، والكائنات الحية في الكركم هذه المشاريع الدوائية، تم تقييم الربات المجهزة المطورة حديثاً لقدرتها على ممارسة إنتاج مضادات البكتيريا بالبحث وكذلك إمكانية عملها كمضادات للالتهاب في البكتيريا على عدة جلديات مختلفة، وباختصار، قمنا بتطوير العديد من المواد المجهزة الأخرى التي تظهر كل من خصائص مضادات للجراثيم ومضادة للالتهاب على الرغم من أن الكائنات الحية ليست قوية مقارنة المركبات الفيسيولوجية، لكنها تعتبر بناءاً على ركز مهماً من التعديل الهيكلي للحصول على مشتقات أكثر فعالية.